Services on Demand
Brazilian Journal of Cardiovascular Surgery
Print version ISSN 0102-7638
On-line version ISSN 1678-9741
BACCO, Felipe W. de et al. St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival. Rev Bras Cir Cardiovasc [online]. 2005, vol.20, n.4, pp.423-431. ISSN 0102-7638. http://dx.doi.org/10.1590/S0102-76382005000400011.
OBJECTIVE: The objective of this work is to present long-term results of valve replacement using SJM-BiocorTM bovine pericardial bioprostheses. METHODS: From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean: 60.6 ± 14.3 years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival. RESULTS: Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcic degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcic degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187): 82.0 ± 13.3% vs. 58.8 ± 13.6% in the 9th year. Event-free survival was 77.5 ± 3.7% for 5th year and 40.2 ± 9.0% for 10th year. Overall estimative of structural failure for a SJM-BiocorTM was 5% in 5th year increasing to 20% in the 10th year. In the aortic position the values were zero and 8%, respectively. Considering current clinical conditions, 88.5% are in NYHA class I, 9.1% in class II and 2.3% in class III. CONCLUSIONS: SJM-BiocorTM bovine pericardial bioprostheses resulted in satisfactory survival of patients, related to low prevalence of bioprosthesis dysfunction.
Keywords : Bioprosthesis; Heart valve prosthesis; Heart valves.